All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Kura Oncology, Syndax, Abbvie, Thermo Fisher and Johnson & Johnson. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View AML content recommended for you
Revumenib in NPM1m and KMT2Ar AML: Highlights from ASH 2025
Do you know... Which of the following best reflects the recent clinical data presented for revumenib at the 67th ASH Annual Meeting and Exposition?
We summarize emerging safety and efficacy data for revumenib in newly diagnosed and relapsed/refractory NPM1-mutated or KMT2A-rearranged acute myeloid leukemia, presented at the 67th American Society of Hematology Annual Meeting and Exposition; Dec 6–9, 2025; Orlando, US.
This educational resource is independently supported by Syndax. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.
References
Jen W-Y. Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. Oral Abstract #47. Presented at: 67th American Society of Hematology Annual Meeting and Exposition; Dec 6–9, 2025; Orlando, US.
Arellano M. Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study. Poster #3418. Presented at: 67th American Society of Hematology Annual Meeting and Exposition; Dec 6–9, 2025; Orlando, US.
Aldoss I. Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708. Poster #3425. Presented at: 67th American Society of Hematology Annual Meeting and Exposition; Dec 6–9, 2025; Orlando, US.
Mims AS. Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b ETCTN 10596 study. Poster #5206. Presented at: 67th American Society of Hematology Annual Meeting and Exposition; Dec 6–9, 2025; Orlando, US.
Iqbal U. Early real-world experience with revumenib outside of a clinical trial setting: A single center retrospective review of efficacy and tolerability. Poster #3448. Presented at: 67th American Society of Hematology Annual Meeting and Exposition; Dec 6–9, 2025; Orlando, US.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
Where do you see the greatest future value for NGS-based MRD assessment in AML/MDS?
